Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes
Human Antibodies · 2025
DOI: 10.1177/10932607241301699 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Antibodies, 2025. Verfasst von Anuja Anil Mandavkar und 18 weiteren Autor:innen. Beteiligte Einrichtung: Vilasrao Deshmukh Government Medical College, Latur, Maharashtra, India. Hauptthemen laut MEDLINE: Multiple Myeloma, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 124 Literaturangaben.
Abstract (Originalsprache)
Background
Multiple Myeloma is a hematological malignancy characterized by the proliferation of clonal plasma cells and associated with severe clinical manifestations. Despite advancements in diagnosis and management, Multiple Myeloma remains incurable, necessitating further research into more effective therapies.
Aim
The primary objective of this review is to provide an informative and critical summary of the Multiple Myeloma microenvironment, and emerging revolutionary therapeutic approaches with potential combination therapy to improve the quality of life for Multiple Myeloma patients. Emerging approaches: Recent advancements in immunotherapy, particularly immune checkpoint inhibitors (ICIs), have shown improvements in immune response against Multiple Myeloma. ICIs target inhibitory pathways such as PD-1/PD-L1 and CTLA-4, potentially overcoming tumor-induced immunosuppression. Combination therapies integrate ICIs with proteasome inhibitors, immunomodulators, and monoclonal antibodies to enhance the anti-tumor immune response. Additionally, Chimeric Antigen Receptor T-cell (CAR-T) therapy has demonstrated effectiveness against Multiple Myeloma, particularly when coupled with ICIs to decrease resistance and relapse. Challenges: Although the efficacy of ICIs in treating Multiple Myeloma has been hindered by the complexity of the tumor microenvironment and immune evasion mechanisms, this challenge has led to the exploration of combination therapies. Potential side effects are still a big challenge for newly recognized ICIs and combination treatment. Future directions: Investigations of new immune checkpoints and the development of targeted therapies against these markers are in progress, creating possibilities for more personalized and effective treatment strategies. Continuous research and robust clinical trials are needed to comprehend the complex dynamics of the Multiple Myeloma microenvironment to develop revolutionary therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vilasrao Deshmukh Government Medical College, Latur, Maharashtra, India.
- Ramaiah Medical College Hospital, Bangalore, India.
- SV Medical College, Tirupati, Andhra Pradesh, India.
- Shadan Institute of Medical Sciences, Hyderabad, Telangana, India.
- Mid and South Essex NHS Foundation Trust, Southend University Hospital, Southend-on-Sea Essex, England.
- Dr. N D Desai Faculty of Medical Science and Research, Nadiad, Gujarat, India.
Zitieren
APA
Mandavkar, A. A., Padakanti, S. S. N., Gupta, S., Akram, S., Jaffar, N., Chauhan, J., Allu, L. R., Saini, P., Nasrallah, J., Omar, M. A., Mugibel, M. A., Syed, S., Ravindran, K. O., Dwivedi, A., Dhingra, G. S., Dhingra, A., Kakadiya, J., Kotaich, J., & Beniwal, S. S. (2025). Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes. Human Antibodies. https://doi.org/10.1177/10932607241301699
Vancouver
Mandavkar AA, Padakanti SSN, Gupta S, Akram S, Jaffar N, Chauhan J, et al. Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes. Human Antibodies. 2025. doi:10.1177/10932607241301699
BibTeX
@article{Mandavkar2025,
author = {Mandavkar, Anuja Anil and Padakanti, Suraj Sai Nikhil and Gupta, Srajan and Akram, Samiyah and Jaffar, Nida and Chauhan, Jugalkishor and Allu, Likhita Reddy and Saini, Pulkit and Nasrallah, Jamil and Omar, Mohamed Abdullahi and Mugibel, Muna Ali and Syed, Saif and Ravindran, Kumaran Ottilingam and Dwivedi, Ayush and Dhingra, Gurneet Singh and Dhingra, Avleen and Kakadiya, Jay and Kotaich, Jana and Beniwal, Shreya Singh},
title = {Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes},
journal = {Human Antibodies},
year = {2025},
doi = {10.1177/10932607241301699}
}
EUVIMED